Interaction of Human Serum Albumin with Uremic Toxins: The Need of New Strategies Aiming at Uremic Toxins Removal

Overview

Journal Membranes (Basel)

Date 2022 Mar 24

PMID 35323736

Authors

Fahimeh Zare

Adriana Janeca

Seyyed M Jokar

Monica Faria

Maria Clara Goncalves

Affiliations

Soon will be listed here.

Abstract

Chronic kidney disease (CKD) is acknowledged worldwide to be a grave threat to public health, with the number of US end-stage kidney disease (ESKD) patients increasing steeply from 10,000 in 1973 to 703,243 in 2015. Protein-bound uremic toxins (PBUTs) are excreted by renal tubular secretion in healthy humans, but hardly removed by traditional haemodialysis (HD) in ESKD patients. The accumulation of these toxins is a major contributor to these sufferers' morbidity and mortality. As a result, some improvements to dialytic removal have been proposed, each with their own upsides and drawbacks. Longer dialysis sessions and hemodiafiltration, though, have not performed especially well, while larger dialyzers, coupled with a higher dialysate flow, proved to have some efficiency in indoxyl sulfate (IS) clearance, but with reduced impact on patients' quality of life. More efficient in removing PBUTs was fractionated plasma separation and adsorption, but the risk of occlusive thrombosis was worryingly high. A promising technique for the removal of PBUTs is binding competition, which holds great hopes for future HD. This short review starts by presenting the PBUTs chemistry with emphasis on the chemical interactions with the transport protein, human serum albumin (HSA). Recent membrane-based strategies targeting PBUTs removal are also presented, and their efficiency is discussed.

Citing Articles

Binding and detoxification efficiency of albumin decline after haemodialysis.

Boss K, Waterstradt K, Schnurr K, Paar M, Stolpe S, Ickerott P Nephrol Dial Transplant. 2023; 39(2):215-221.

PMID: 37558390 PMC: 10828194. DOI: 10.1093/ndt/gfad133.

Improving Structural Homogeneity, Hydraulic Permeability, and Mechanical Performance of Asymmetric Monophasic Cellulose Acetate/Silica Membranes: Spinodal Decomposition Mix.

Zare F, Goncalves S, Faria M, Goncalves M Membranes (Basel). 2023; 13(3).

PMID: 36984734 PMC: 10059883. DOI: 10.3390/membranes13030346.

A Novel Strategy for Enhanced Sequestration of Protein-Bound Uremic Toxins Using Smart Hybrid Membranes.

Lopes M, Pires R, Faria M, Bonifacio V J Funct Biomater. 2023; 14(3).

PMID: 36976062 PMC: 10059720. DOI: 10.3390/jfb14030138.

Adsorption- and Displacement-Based Approaches for the Removal of Protein-Bound Uremic Toxins.

Rodrigues F, Faria M Toxins (Basel). 2023; 15(2).

PMID: 36828424 PMC: 9963700. DOI: 10.3390/toxins15020110.

References

Niwa T . Organic acids and the uremic syndrome: protein metabolite hypothesis in the progression of chronic renal failure. Semin Nephrol. 1996; 16(3):167-82. View

Tsutsumi Y, Maruyama T, Takadate A, Shimada H, Otagiri M . Decreased bilirubin-binding capacity in uremic serum caused by an accumulation of furan dicarboxylic acid. Nephron. 2000; 85(1):60-4. DOI: 10.1159/000045631. View

Li J, Wang Y, Xu X, Cao W, Shen Z, Wang N . Improved dialysis removal of protein-bound uremic toxins by salvianolic acids. Phytomedicine. 2019; 57:166-173. DOI: 10.1016/j.phymed.2018.12.018. View

Meijers B, Bammens B, Moor B, Verbeke K, Vanrenterghem Y, Evenepoel P . Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int. 2008; 73(10):1174-80. DOI: 10.1038/ki.2008.31. View

Vaziri N, Wong J, Pahl M, Piceno Y, Yuan J, DeSantis T . Chronic kidney disease alters intestinal microbial flora. Kidney Int. 2012; 83(2):308-15. DOI: 10.1038/ki.2012.345. View

Meijers B, de Loor H, Bammens B, Verbeke K, Vanrenterghem Y, Evenepoel P . p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients. Clin J Am Soc Nephrol. 2009; 4(12):1932-8. PMC: 2798868. DOI: 10.2215/CJN.02940509. View

Deguchi T, Isozaki K, Yousuke K, Terasaki T, Otagiri M . Involvement of organic anion transporters in the efflux of uremic toxins across the blood-brain barrier. J Neurochem. 2006; 96(4):1051-9. DOI: 10.1111/j.1471-4159.2005.03550.x. View

Pavlenko D, van Geffen E, van Steenbergen M, Glorieux G, Vanholder R, Gerritsen K . New low-flux mixed matrix membranes that offer superior removal of protein-bound toxins from human plasma. Sci Rep. 2016; 6:34429. PMC: 5050520. DOI: 10.1038/srep34429. View

Kabanda A, Jadoul M, Pochet J, Lauwerys R, Van Ypersele De Strihou C, Bernard A . Determinants of the serum concentrations of low molecular weight proteins in patients on maintenance hemodialysis. Kidney Int. 1994; 45(6):1689-96. DOI: 10.1038/ki.1994.221. View

10.

Schepers E, Meert N, Glorieux G, Goeman J, Van der Eycken J, Vanholder R . P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant. 2006; 22(2):592-6. DOI: 10.1093/ndt/gfl584. View

11.

Hida M, Aiba Y, Sawamura S, Suzuki N, Satoh T, Koga Y . Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron. 1996; 74(2):349-55. DOI: 10.1159/000189334. View

12.

Farrell P, Gotch F, Peters J, BERRIDGE Jr B, Lam M . Binding of hippurate in normal plasma and in uremic plasma pre- and postdialysis. Nephron. 1978; 20(1):40-6. DOI: 10.1159/000181194. View

13.

Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P . Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003; 63(5):1934-43. DOI: 10.1046/j.1523-1755.2003.00924.x. View

14.

Miyazaki H, Anzai N, Ekaratanawong S, Sakata T, Shin H, Jutabha P . Modulation of renal apical organic anion transporter 4 function by two PDZ domain-containing proteins. J Am Soc Nephrol. 2005; 16(12):3498-506. DOI: 10.1681/ASN.2005030306. View

15.

Suzuki T, Toyohara T, Akiyama Y, Takeuchi Y, Mishima E, Suzuki C . Transcriptional regulation of organic anion transporting polypeptide SLCO4C1 as a new therapeutic modality to prevent chronic kidney disease. J Pharm Sci. 2011; 100(9):3696-707. DOI: 10.1002/jps.22641. View

16.

WENGLE B, Hellstrom K . Volatile phenols in serum of uraemic patients. Clin Sci. 1972; 43(4):493-8. DOI: 10.1042/cs0430493. View

17.

Lin C, Wu C, Pan C, Chen Y, Sun F, Chen H . Serum protein-bound uraemic toxins and clinical outcomes in haemodialysis patients. Nephrol Dial Transplant. 2010; 25(11):3693-700. DOI: 10.1093/ndt/gfq251. View

18.

Nagata Y, Kusuhara H, Endou H, Sugiyama Y . Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus. Mol Pharmacol. 2002; 61(5):982-8. DOI: 10.1124/mol.61.5.982. View

19.

Tanaka A, Takahashi Y, Mizokuchi M, Shimada N, Koide H . Plasma, urinary, and erythrocyte concentrations of guanidino compounds in patients with chronic renal failure. Ren Fail. 1999; 21(5):499-514. DOI: 10.3109/08860229909045190. View

20.

De Deyn P, Macdonald R . Guanidino compounds that are increased in cerebrospinal fluid and brain of uremic patients inhibit GABA and glycine responses on mouse neurons in cell culture. Ann Neurol. 1990; 28(5):627-33. DOI: 10.1002/ana.410280505. View